title: Translocation (12;15)(p13;q13) in a patient with relapsed acute myeloid leukemia.
abstract: We report a patient with a history of leukopenia who developed acute myeloid leukemia (AML) FAB M2 and was successfully treated with induction and consolidation chemotherapy. She relapsed 7 months after initial diagnosis. Peripheral blood cells at relapse showed a t(12;15)(p13;q13), which has not been previously described in de novo or relapsed AML.
authors.affiliation: Division of Hematology/Oncology, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, California, 90048, USA.
authors.forename: S W
authors.initials: SW
authors.lastname: Lim
authors.forename: R E
authors.initials: RE
authors.lastname: Falk
authors.forename: R M
authors.initials: RM
authors.lastname: Look
authors.forename: M M
authors.initials: MM
authors.lastname: Fuerst
authors.forename: G N
authors.initials: GN
authors.lastname: Lawrence
authors.forename: D A
authors.initials: DA
authors.lastname: Kusuanco
authors.forename: F J
authors.initials: FJ
authors.lastname: Giles
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002881:Chromosomes, Human, Pair 12; D002884:Chromosomes, Human, Pair 15; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000235:genetics*; D012008:Recurrence; D014178:Translocation, Genetic
chemical_list: D003561:Cytarabine; D015255:Idarubicin; D003630:Daunorubicin